CHDI
Proteome Sciences to collaborate with CHDI Foundation on Huntington’s disease research
London, UK. Proteome Sciences plc (Proteome) has announced that they will collaborate with CHDI Foundation, Inc. on a systems biology project regarding Huntington’s disease. Initially, Proteome will provide its PS Biomarker Services™ protein pro ...Read More
GNS Healthcare And CHDI Foundation Collaborate To Build Computer Model Of Huntington’s Disease
Cambridge, MA, and New York, NY – GNS Healthcare, Inc. (GNS), the leading healthcare data analytics company focused on enabling personalized medicine to improve human health, today announced that it has entered into a collaboration with CHDI Found ...Read More
Thomson Reuters Partners with CHDI Foundation to Develop Systems Biology Tools for Huntington’s Disease
Philadelphia, PA, The Intellectual Property & Science business of Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, today announced a collaboration with CHDI Foundation, Inc. to develop syste ...Read More
Lundbeck and CHDI Foundation announce research collaboration to investigate candidate therapy for Huntington’s disease
Deerfield, Ill., – CHDI Foundation, Inc. and Lundbeck today announced a research collaboration to investigate a targeted therapy for Huntington’s disease (HD). Currently, no treatment exists to slow or halt the progression of HD,1 a ...Read More
KineMed and CHDI Foundation collaborate to develop new biomarkers of disease progression and to evaluate potential therapeutics for Huntington’s disease
Emeryville, CA and New York, NY, KineMed, Inc. (www.kinemed.com) and CHDI Foundation, Inc. announced today a collaboration to use KineMed’s isotopic labeling and dynamic proteomics platform to investigate the t ...Read More
Galenea and CHDI Foundation announce collaboration to identify key synaptic dysfunction in Huntington’s disease
Cambridge, MA and New York, NY, Galenea Corp. and CHDI Foundation, Inc. have announced a collaboration to identify synaptic dysfunction linked to >Huntington’s disease (HD) utilizing Galenea’s proprietary synaptic transmission drug discovery p ...Read More
Cristina Sampaio, MD, PhD, joins CHDI Foundation as Chief Clinical Officer
New York, CHDI Foundation, Inc. has appointed Cristina Sampaio, MD, PhD, as Chief Clinical Officer. In this newly-created position Sampaio will lead and develop CHDI’s clinical programs by building both internal capabilities and further developing ...Read More
Isis and CHDI Renew Collaboration
Carlsbad, California - Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and CHDI Foundation, Inc. announced today a renewal of their collaboration to discover and develop an antisense drug for the treatment of Huntington’s disease (HD), a fatal neurodege ...Read More
CHDI and FMI Collaboration
New York, CHDI Foundation, Inc. has entered into collaboration with the Friedrich Miescher Institute for Biomedical Research (FMI) to develop an assay to quantify huntingtin, the protein that causes Huntington’s disease (HD). FMI and CHDI will col ...Read More
Sangamo BioSciences and CHDI Foundation announce collaboration to develop ZFP Therapeutic® for Huntington’s disease
Richmond, California and New York – Sangamo BioSciences, Inc. (Nasdaq: SGMO) and CHDI Foundation, Inc. have announced a collaboration to develop a novel therapeutic for Huntington’s disease (HD) based on Sangamo’s proprieta ...Read More